Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea

References

• Hamman RF. Genetic and environmental determinants of non-insulin-dependent diabetes mellitus (NIDDM). Diabetes Metab Rev 1992;8:287-338
   PubMed Web of Science ®Google Scholar
• World Health Organization. Diabetes. World Health Organization, September 2012. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/[Last accessed 30 June 2014]
   Google Scholar
• Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011;378:169-81
   PubMed Web of Science ®Google Scholar
• Mathers C, Boerma T, Fat DM, et al. The Global Burden of Disease, 2008. World Health Organization. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf
   Google Scholar
• National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. Report No.: NICE clinical guideline 87 – type 2 diabetes. London, UK: National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at NICE, May 2009
   Google Scholar
• Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009;180:385-97
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Forxiga: EPAR – Information. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdf [Last accessed 16 September 2013]
   Google Scholar
• Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-31
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014;16:124-36
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33
   PubMed Web of Science ®Google Scholar
• Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea. Identifier NCT01128153. Bethesda (MA): 2013. ClinicalTrials.gov [Last accessed 30 June 2014]
   Google Scholar
• CADTH Optimal Use Report – Third-line pharmacotherapy for Type 2 Diabetes – Update. CADTH 2013 Vol.3, no.1b. Available at: http://www.cadth.ca/media/pdf/OP0512_Diabetes%20Update_Third-line_e.pdf [Last accessed 30 June 2014]
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Clinical Review: Third-line therapy for patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea. CADTH, 2010. Available at: https://www.cadth.ca/second-and-third-line-therapies-type-2-diabetes [Last accessed 6 January 2014]
   Google Scholar
• Dias S, Welton N, Sutton A, Ades A. NICE DSU Technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. NICE, 2011. Available at: www.nicedsu.org.uk [Last accessed 30 June 2014]
   Google Scholar
• Alshaikh AR. Comparison of basal insulin added to oral agents versus twice daily premixed insulin as initial insulin therapy for type 2 diabetes. Pak J Med Sci 2006;22:14-17
   Google Scholar
• Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004;116:230-5
   PubMed Web of Science ®Google Scholar
• Bell DS, Dharmalingam M, Kumar S, Sawakhande RB. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II). Diabetes Obes Metab 2011;13:800-5
   PubMed Web of Science ®Google Scholar
• Bergenstal R, Lewin A, Bailey T, et al. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 2009;25:65-75
   PubMed Web of Science ®Google Scholar
• Davies MJ, Thaware PK, Tringham JR, et al. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin. Diabet Med 2007;24:714-19
   PubMed Web of Science ®Google Scholar
• Diamant M, Van GL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43
   PubMed Web of Science ®Google Scholar
• Dorkhan M, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. Cardiovasc Diabetol 2009;8:15
   PubMed Web of Science ®Google Scholar
• Goudswaard AN, Stolk RP, Zuithoff P, et al. Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. J Fam Pract 2004;53:393-9
   PubMed Web of Science ®Google Scholar
• Hartemann-Heurtier A, Halbron M, Golmard JL, et al. Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes Res Clin Pract 2009;86:37-43
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
   PubMed Web of Science ®Google Scholar
• Herman WH, Buse JB, Arakaki RF, et al. Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy. Endocr Pract 2011;17:563-7
   PubMed Web of Science ®Google Scholar
• Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
   PubMed Web of Science ®Google Scholar
• Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-9
   PubMed Web of Science ®Google Scholar
• Liu SC, Chien KL, Wang CH, et al. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea. Endocr Pract 2013;19:980-8
   PubMed Web of Science ®Google Scholar
• Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-67
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508-15
   PubMed Web of Science ®Google Scholar
• Stehouwer MH, DeVries JH, Lumeij JA, et al. Combined bedtime insulin – daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate – a randomised trial. Diabetes Metab Res Rev 2003;19:148-52
   PubMed Web of Science ®Google Scholar
• Strojek K, Bebakar WMW, Khutsoane DT, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009;25:2887-94
   PubMed Web of Science ®Google Scholar
• Charpentier G, Halimi S. Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes Obes Metab 2009;11:844-54
   PubMed Web of Science ®Google Scholar
• AstraZeneca BMS. A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb Study to Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin and Sulfonylurea in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Combination of Metformin and Sulfonylurea. ClinicalTrials.gov, 8 July 2012. Available at: http://clinicaltrials.gov/ct2/show/results/NCT01128153?sect=X6015#outcome1 [Last accessed 30 June 2014]
   Google Scholar
• Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45
   PubMed Web of Science ®Google Scholar
• Home P, Stewart M, Yang F, et al. 52-Week Efficacy of Albiglutide vs Placebo and vs Pioglitazone in Triple Therapy (Background Metformin and Glimepiride) in People with Type 2 Diabetes: HARMONY5 Study (58-LB). American Diabetes Association 73rd Scientific Sessions, 2013
   Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24
   PubMed Web of Science ®Google Scholar
• Lukashevich V, Prato SD, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab 2014;16:403-9
   PubMed Web of Science ®Google Scholar
• Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011;28:1352-61
   PubMed Web of Science ®Google Scholar
• Round E, Shentu Y, Golm GT. Safety and Efficacy of Sitagliptin Added to the Combination of Sulfonylurea and Metformin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (1148-P). American Diabetes Association 73rd Scientific Sessions, 2013
   Google Scholar
• Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 2009;52:2046-55
   PubMed Web of Science ®Google Scholar
• Matthaei S, Rohwedder K, Grohl A, Johnsson E. Dapagliflozin improves glycaemic control and reduces body weight as add-on therapy to metformin plus sulphonylurea (PS-073). Diabetologia 2013:56
   Web of Science ®Google Scholar
• Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013;67:1267-82
   PubMed Web of Science ®Google Scholar
• Lu CH, Wu TJ, Shih KC, et al. Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus. J Formos Med Assoc 2013;112:144-50
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance to Industry Developing Products for Weight Management. 2007. Published by the FDA. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071612.pdf Last accessed 30 June 2014
   Google Scholar
• A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication. ClinicalTrials.gov, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01195662 [Last accessed 30 September 2013]
   Google Scholar
• A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB). ClinicalTrials.gov, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01137474 [Last accessed 30 September 2013]
   Google Scholar
• Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012;157:601-10
   PubMed Web of Science ®Google Scholar
• Li Y, Hu Y, Ley SH, et al. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Diabetes Care 2014;37:3106-13
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
   PubMed Web of Science ®Google Scholar
• Lambert PC, Sutton AJ, Burton PR, et al. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 2005;24:2401-28
   PubMed Web of Science ®Google Scholar
• Scott DA, Boye KS, Timlin L, et al. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab 2013;15:213-23
   PubMed Web of Science ®Google Scholar